Key result
High-dose aprotinin cuts postoperative blood loss ~46% vs placebo in adults undergoing cardiopulmonary bypass.
Why the study?
The efficacy and safety of a high-dose regimen of aprotinin in routine cardiac operations were assessed due to the need for effective blood loss reduction strategies.
Does a high-dose regimen of aprotinin reduce postoperative blood loss and transfusion needs in adult patients undergoing cardiopulmonary bypass?
Population
93 adult patients undergoing cardiopulmonary bypass for routine cardiac operations
Comparison
High-dose aprotinin regimen vs placebo (normal saline)
Design
Placebo-controlled randomized double-blind study
Follow-up
Until removal of thoracic drains
Authors
Loading...
High-dose aprotinin offers a strategy to limit blood loss in cardiopulmonary bypass; confirms efficacy versus placebo in this RCT.
RCT (n=93)
Double-blind
randomized
Does a high-dose regimen of aprotinin reduce postoperative blood loss and transfusion needs in adult patients undergoing cardiopulmonary bypass?
Absolute Event Rate: 1051% vs 1933%
p-value: p=< 0.001
A high-dose regimen of aprotinin significantly reduces postoperative blood loss and transfusion requirements in adult patients undergoing cardiopulmonary bypass.
Rodrigus et al. (1996) conducted an RCT in Cardiopulmonary bypass for aortocoronary bypass and valve replacement (n=93). Aprotinin vs. Normal saline was evaluated on Mean total postoperative blood loss until removal of thoracic drains (ml) (p=< 0.001). A high-dose regimen of aprotinin significantly reduced mean total postoperative blood loss compared to placebo (1051 ml vs 1933 ml; p < 0.001) in adults undergoing cardiopulmonary bypass.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: